Ventum Financial Lowers Sernova (TSE:SVA) Price Target to C$2.50

Sernova (TSE:SVA) had its price objective decreased by Ventum Financial from C$3.00 to C$2.50 in a research note released on Friday, BayStreet.CA reports. Ventum Financial currently has a buy rating on the stock.

Separately, Leede Financial decreased their price target on shares of Sernova from C$3.00 to C$1.50 and set a speculative buy rating on the stock in a research report on Friday.

Sernova Trading Down 5.8 %

TSE:SVA opened at C$0.25 on Friday. The company’s 50 day moving average is C$0.27 and its 200-day moving average is C$0.37. The company has a quick ratio of 18.11, a current ratio of 0.62 and a debt-to-equity ratio of 16.55. Sernova has a 12 month low of C$0.20 and a 12 month high of C$0.83. The firm has a market cap of C$79.48 million, a price-to-earnings ratio of -1.88 and a beta of 1.38.

Sernova (TSE:SVA) last posted its quarterly earnings data on Friday, June 14th. The company reported C($0.03) EPS for the quarter, hitting analysts’ consensus estimates of C($0.03). Equities analysts anticipate that Sernova will post -0.08 EPS for the current year.

Insiders Place Their Bets

In other news, Director Steven Sangha sold 930,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of C$0.24, for a total transaction of C$223,200.00. Over the last quarter, insiders have acquired 359,600 shares of company stock valued at $92,771. 12.98% of the stock is currently owned by corporate insiders.

Sernova Company Profile

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.